Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-operative Nivolumab With or Without Relatlimab in Stage II-IIIa Urothelial Cancer
NCT06237920Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Feb 2024
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of relatlimab in urothelial carcinoma (UC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Pathological complete response. Started Feb 2024; status: active, not recruiting.
02
Drugs
relatlimab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06237920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06237920.